64 results about "Dissociation rate" patented technology

The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (k_on) of at least 2×10⁵ M⁻¹s⁻¹ and a dissociation rate (k_off) of less than 5×10⁻⁴ s⁻¹.

The invention relates to an analytical measuring and evaluation method for determining the interaction parameters between an analyte and a ligand, preferably in a biosensor. According to the inventive method, the concentration of the analyte is gradually changed at defined intervals ti and the initial association or dissociation rates or association and dissociation constants are determined. The invention further relates to a device for carrying out the inventive method.

The present of disclosure provides variant Pol6 polymerase polypeptide, compositions comprising the Pol6 variant polypeptides, and methods for using the variant Pol6 polypeptides for determining the sequencing of nucleic acids, for example, by nanopore sequencing. The variant Pol6 polymerases possess decreased rates of dissociation of template from the polymerase-template complex, which result n increased processivity relative to the parental Pol6 polypeptides from which they are derived.

The invention discloses an encoding/decoding method and device for orthogonal repeated accumulate codes. In encoding, a repeatedly encoding submodule conducts code block segmentation, CRC (cyclic redundancy check), Turbo encoding and code block cascade to input TB bit information so as to obtain a repeated encoding bit sequence; the repeated encoding bit sequence is multiplexed with control information and then interleaved by a channel and processed by a modulation submodule for orthogonal accumulate encoding; further, the information is subjected to transmission precoding/RE mapping, and CP adding on IFFT, and then is transmitted; in decoding, the accumulative relationship of all codes in a receiving estimating sequence is relieved; then a modulation code estimating sequence is subjected to flexible modulation and channel de-interleaving in sequence, the processed information is sent to a repeated decoding submodule; and code block segmentation, dissociation rate matching, Turbo decoding, CRC decoding and code block cascade are conducted in sequence to complete decoding. The encoding/decoding method and device can effectively improve the system decoding performance in a serious multipath fading condition, and reduce the processing cost of the system and the processing time delay.

The invention discloses a dissociation rate matching method and a device, which are used for a dissociation rate matching system. The system comprises a plurality of sub-random access memories (sub-RAMs) for storing input data, wherein the number of the sub-RAMs is the same as the maximum number of repeated sending supported by a receiver of a matching system. The method comprises the following steps: determining the sub-RAM in which the input data needs to be stored and the position of the input data in the sub-RAM based on the address of the received input data, and storing the repetitive input data for each time in different sub-RAMs in parallel; determining the corresponding address of the data serial number in a soft buffer at the sending end of the matching system in the input RAM of a decoder by the deinterleaving calculation; determining and withdrawing the input data from the sub-RAM when the corresponding address in the input RAM needs to be filled with data; and determining the data to be written based on the withdrawn input data, and writing the data to be written in the corresponding address in the input RAM. By using the invention, the processing efficiency at the bit level can be improved.

The invention discloses a device and method for preparing single crystal diamonds by laser enhanced plasma CVD. The device comprises plasma CVD equipment and laser equipment, wherein more than 1 set of laser equipment is respectively positioned on the outside of a cylindrical cavity of the plasma CVD equipment, laser emitted by the laser equipment can irradiate onto a substrate table positioned inthe cavity of the plasma CVD equipment; the substrate table is positioned in the middle of the cavity of the plasma CVD equipment, a cooling water circulation system is arranged at the lower part ofthe substrate table and comprises a cooling water inlet and a cooling water outlet; and a raw material gas inlet and an extraction opening are formed in the bottom of the cavity of the plasma CVD equipment. The method combines microwave energy (or electric energy) with laser energy and improves the energy of plasma and the gas dissociation rate in a diamond synthesizing process by using low-cost high-energy laser, thereby improving the synthetic rate of the diamonds and effectively solving the problem of high-speed mass preparation of diamonds.

There is provided a method of quantitatively ranking transient ligand binding to target biomolecules by means of NMR relaxation dispersion profiles. The present invention also relates to a method to identify ligand site obeying two-state and more complex binding behavior in a transient complex of a ligand with a target molecule, still with the use of NMR. There is also provided an efficient method to quantitate fast dissociation rates of ligands containing at least one magnetic nuclei by performing NMR relaxation dispersion experiments at different protein concentrations, enabling the evaluation of populations and exchange rates, and extending the practical applicability of the NMR relaxation dispersion experiments.

The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-α and that are capable of neutralizing TNF-α at low concentrations. Preferably, the TNF-α binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

The present invention relates to a novel class of fluorescent compounds that bind to histone deacetylases. The fluorescent compounds can be used to determine binding association and dissociation rates of histone deacetylase inhibitors via fluorescence polarization.

The invention relates to the technical field of battery recovery, in particular to a pretreatment method for recycling a waste power lithium battery. The method comprises the following steps of performing perforated discharge on a waste power lithium battery with completely released electrolyte; disassembling the completely-discharged waste power lithium battery, so that a battery shell and a battery inner core are obtained; performing low-temperature heat treatment on positive and negative electrode materials, and damaging the bonding effect of an adhesive PVDF; performing shearing type crushing on the positive and negative electrode materials which are already subjected to low-temperature heat treatment; and carrying out ultrasonic cleaning on an aluminum foil and a copper foil in the primary dissociation material, so as to obtain the aluminum foil and the copper foil which are completely dissociated from a lithium iron phosphate powder coating layer and a carbon powder coating layer, wherein the dissociation rate reaches 90%-95%. By adoption of the pretreatment method for recycling the waste power lithium battery, the dissociation rates of lithium battery positive and negative electrode copper foil and the carbon powder coating layer, and the aluminum foil and the lithium iron phosphate powder coating layer are improved, the time for recycling the waste power lithium batteries is shortened, and then the recovery efficiency of the waste power lithium batteries is improved.

The invention relates to an anti-human VEGF monoclonal antibody and a coding nucleic acid sequence thereof, and especially relates to an anti-human VEGF monoclonal antibody having a high affinity and a low dissociation rate. The preferable anti-human VEGF monoclonal antibody comprises a human Fc region, a framework region, and a human light-chain and/or heavy-chain variable region obtained through molecular evolution. The invention also discloses medicinal compositions composed of the human antibody, an application of the human antibody in human disease treatment, and a method for using the human antibody in the treatment.

The invention relates to a fully humanized antihuman HER2 monoclonal antibody, particularly an antihuman HER2 monoclonal antibody having high affinity and low dissociation rate. The antihuman HER2 monoclonal antibody preferred by the invention comprises a fully humanized Fc region, a framework region, and a CDR region of a fully humanized light chain and/or heavy chain, wherein the CDR region is obtained by molecular evolution. The invention also discloses an application of a medicine composition consisting of the antihuman HER2 monoclonal antibody in treating human diseases and a method for using the antihuman HER2 monoclonal antibody in treatment.

An object of the present invention is to provide a method for measuring a rate coefficient by surface plasmon resonance analysis with excellent accuracy, reliability, and cost performance that can improve the assay accuracy and simplify the apparatus. The present invention is provides a method for determining the adsorption rate coefficient (Ka) and the dissociation rate coefficient (Kd) of the reaction between an analyte molecule immobilized on a metal surface and a molecule that interacts with the analyte molecule by measuring changes in surface plasmon resonance signals using a surface plasmon resonance measurement device and performing fitting to a signal curve obtained by such measurement, wherein fitting is performed to the signals from which data obtained at the time of liquid exchange and data obtained at a given time point thereafter have been removed, and that an algorithm is adopted wherein the fitted curve passes through a point representing a baseline value obtained at the time of liquid exchange or immediately therebefore.

The invention provides a method for evaluating influences of drugs on inter-module relations in a biomolecule network, and the method targets complex networks of biomolecules, such as a protein-protein interaction network, a gene expression regulation network, a biological metabolism network, an epigenetic network, a phenotype network and a signal transduction network. The method mainly comprises the steps that module recognition is performed on the biomolecule network before and after drug intervention; inter-module direct relation parameters and inter-module indirect relation parameters are calculated, screened and integrated based on two groups of recognized modules to obtain inter-module coordination coefficients of two arbitrary modules in each group of modules; a module network is constructed based on the inter-module coordination coefficients; and module network topological parameters before drug intervention and module network topological parameters after drug intervention are compared, or module network connectors before and after drug intervention are recognized, and the dissociation rate of the connectors is calculated.

The invention provides a nitriding device for a cast-iron piston ring and a nitriding process thereof, wherein the nitriding device comprises a nitriding furnace, and the nitriding furnace is provided with a nitrogen inlet pipe, an ammonia gas inlet pipe, a mixed gas outlet pipe, a carbon tetrachloride titration device and an indicating device for the pressure inside the furnace; the other end of the mixed gas outlet pipe is connected with a determinator for ammonia dissociation rate. The process comprises: the preparation before nitriding, the preparation period, the temperature-rise period and the temperature-fall period of the nitriding process. The device of the invention has the advantages of reasonable structure, reasonable process flow, simple operation, low production cost, reliable performance of the treated product and further has the advantages of completely meeting client requirements, being applicable to the nitriding of vehicle cast-iron piston rings, gas rings or oil rings, meeting market requirements and having pretty high economic benefit.

A method of increasing the affinity and/or decreasing the off-rate of a given TCR specific for a given target pMHC, comprising creating a plurality of TCRs having an α chain CDR2 sequence and/or a β chain CDR2 sequence different from the corresponding CDR2 sequence(s) of the given TCR but having the same α and β CDR1 and CDR3 sequences as the given TCR, determining the affinity and/or off-rate of members of said plurality of TCRs for the target pMHC, and selecting one or more members having at least a 10-fold greater affinity for the target pMHC than the given TCR and/or a 10-fold slower off-rate for the target pMHC than the given TCR.

The invention relates to an anti-human monoclonal antibody and a coding nucleic acid sequence thereof, and especially relates to an anti-human CD20 monoclonal antibody having a high affinity and a low dissociation rate. The preferable anti-human CD20 monoclonal antibody comprises a human Fc region, a framework region, and a human light-chain and/or heavy-chain variable region obtained through molecular evolution. The invention also discloses medicinal compositions composed of the human antibody, an application of the human antibody in human disease treatment, and a method for using the human antibody in the treatment.

The purpose of the present invention is to provide an aptamer for vWF, which is superior in a binding ability, a dissociation rate, and/or stability to the conventional nucleic acid aptamers. The present invention can solve the problem by a DNA aptamer which contains artificial nucleotides and binds to vWF.

The invention discloses a plasma process chamber and a gas injection apparatus for the same. The inner wall of an annular gas injection pipeline is provided with a plurality of gas inlets, an acute angel is formed between a gas output direction and the direction directed towards the circle center of the annular gas injection pipeline by the gas inlet, and it is ensured that gas, after being injected into an reaction chamber, forms eddy current shaped distribution in a dissociation area, so that the gas sinking rate is delayed, the walk distance formed when the gas reaches a substrate is prolonged, and the gas is dissociated as much as possible in the dissociation area. Compared to a conventional gas inlet vertical to the inner wall of the annular gas injection pipeline, the advantages are as follows: the gas sinking rate is slowed, the gas dissociation rate is improved, the reaction gas utilization rate is improved, and at the same time, since the concentration of plasma in the reaction chamber rises, the etching rate is improved.

The invention discloses a preparation method for monoclonal antibodies with functions of anti-tumor angiogenesis. The preparation method comprises the following steps: expression and purification of cell receptor protein VEGFR2, preparation of completely humanized phage Fab antibody libraries, selection of antibodies with high affinity from the phage antibody libraries, immobilization of purified VEGFR2 on CM5 chips of Biacore, testing of association rates and dissociation rates of AVR2 antibodies with different concentrations and VEGFR2 respectively, selection of antibody libraries based on high affinity and high specificity of antibodies and antigens, cloning of antibody genes to expressing cells, construction of engineered cell lines with high expression level, and detection and evaluation of anti-angiogenesis. By utilizing the phage antibody library technology, the preparation method can produce humanized antibodies directly. In addition, the monoclonal antibodies are advantaged by strong drug specificity, minimal side effects and remarkable effects.

A method for obtaining the binding kinetic rate constants using fiber optic particle plasmon resonance (FOPPR) sensor, suitable for a test solution with two or more concentrations, which employs the following major steps: providing one FOPPR sensor instrument system, obtaining optical time-resolved signal intensities starting at the initial time to the steady state of the two or more regions, substituting the measured signal intensity values into the formula which is derived by using the pseudo-first order rate equation model. In addition, this method measures the temporal signal intensity evolution under static conditions as the samples are quickly loaded. As a result, unlike the conventional device where the sample is continuously infused, the method is able to measure the association and dissociation rate constants of which the upper bounds are not limited by the sample flow rate.